Fesoterodine Fumarate Tablet, Film Coated, Extended Release
Product Images NDC 72603-414

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Fesoterodine Fumarate (NDC 72603-414). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rxllc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

4mg-30s (4mg 30s)

4mg-30s (4mg 30s)
Label for Fesoterodine Fumarate Extended-release Tablets 4 mg, film-coated tablets in a package of 30 tablets. The label includes storage instructions, manufacturer information (Annora Pharma Pvt. Ltd., Telangana, India), and states the product is for oral use, manufactured for Northstar Rx LLC, Memphis, TN.*
FDA Label Image

8mg-30s (8mg 30s)

8mg-30s (8mg 30s)
Label for Fesoterodine Fumarate Extended-release Tablets 8 mg, film-coated oral tablets in a 30-count package. The label includes storage instructions, manufacturer and labeler information, and a barcode. Manufactured for Northstar Rx LLC and by Annora Pharma Pvt. Ltd., India.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph showing the change in number of micturitions per 24 hours over 12 weeks for Study 1. The x-axis represents weeks (0, 2, 8, 12) and the y-axis shows the mean change from baseline in number of micturitions per 24 hours, ranging from 0 to -3. Three lines represent placebo, fesoterodine fumarate extended-release tablets 4 mg, and 8 mg, with both dosages showing a larger decrease in micturitions compared to placebo over time.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph titled 'Change in Urge Incontinence Episodes per 24 h (Study 1)' displaying mean change from baseline in urge incontinent episodes over 12 weeks. The graph compares placebo, 4 mg, and 8 mg doses of Fesoterodine fumarate extended-release tablets, showing decreases in episodes for both doses compared to placebo.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
Line graph titled 'Change in Number of Micturitions per 24 h (Study 2)' showing mean change from baseline in number of micturitions over 12 weeks. It compares placebo (N=266), fesoterodine fumarate extended-release tablets 4 mg (N=267), and 8 mg (N=267). Data points show a greater reduction in micturitions for both fesoterodine doses versus placebo over time.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A line graph titled 'Change in Urge Incontinence Episodes per 24 h (Study 2)' depicting the mean change from baseline in urge incontinence episodes over 12 weeks. It compares placebo, 4 mg, and 8 mg doses of Fesoterodine fumarate extended-release tablets. The graph shows a greater reduction in episodes for the 8 mg dose, followed by the 4 mg dose, compared to placebo.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of Fesoterodine Fumarate, showing the molecular arrangement of the active ingredient and fumarate component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.